The pharmaceutical company has bought diabetes management platform MySugr for an undisclosed sum, two years after its corporate venturing unit backed a $4.8m seed round.
Pharmaceutical firm Roche has agreed to acquire one of its portfolio companies, Austria-based diabetes management technology developer MySugr, for an amount a source told Close Concerns was between $75m and $100m.
Founded in 2012, MySugr has created a diabetes management system that incorporates apps which help with coaching, therapy and data tracking, and which integrate with medical devices.
The platform has more than 1 million users across 52 countries, and Roche plans to make MySugr’s technology a key part of…
